Allogeneic Transplantation clinical trials

Explore recruiting allogeneic transplantation clinical trials.

Recruiting allogeneic transplantation studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Allogeneic Transplantation trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Randomized Evaluation of Treosulfan versus Melphalan conditioning fol-lowed by PTCY in Patients with AML and MDS undergoing allogeneic Transplantation (RELEVANT)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

CASPER-ATG-IPC 2023-015 : Reinforced prophylaxis of GVH in elderly patients with haematological malignancies receiving haploidentical allogeneic hematopoietic stem cell transplantation: use of a low dose of post-allograft anti-lymphocytic serum.

France

Therapeutic exploratory (Phase II) EU CTIS Study details

TAGVEN "Open label phase II study evaluating the efficacy and safety of the combination of tagraxofusp and venetoclax in treatment-naive blastic plasmacytoid dendritic cell neoplasm patients"

France

Therapeutic exploratory (Phase II) EU CTIS Study details

MAGIC AML - Multiarm, Multicenter, RAndomized, Molecularly-GuIded Controlled Trial of Personalized Treatment Strategy - of Acute Myeloid Leukemia

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open Label, Phase 2 Study to Evaluate Activity and Safety of Daratumumab in combination with Bortezomib and Dexamethasone in patients with Relapsed or Refractory Plasmablastic lymphoma (DALYA trial)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Role of Vitamin D in GVHD prophylaxis in patients undergoing allogeneic transplantation stem cells. Pilot phase II study randomized open monocentric

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Allogeneic Transplantation trials by city

Allogeneic Transplantation in Toronto Allogeneic Transplantation in Vancouver Allogeneic Transplantation in Montreal Allogeneic Transplantation in Calgary Allogeneic Transplantation in Edmonton Allogeneic Transplantation in Ottawa Allogeneic Transplantation in Winnipeg Allogeneic Transplantation in Quebec City Allogeneic Transplantation in Hamilton Allogeneic Transplantation in Kitchener Allogeneic Transplantation in London Allogeneic Transplantation in Halifax Allogeneic Transplantation in New York Allogeneic Transplantation in Los Angeles Allogeneic Transplantation in Chicago Allogeneic Transplantation in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease